The Phase I portion was a dose-escalation study designed to assess safety and tolerability in
patients with metastatic breast cancer. Phase II was intended to measure response rate in
patients with metastatic breast cancer but did not enroll because the Phase I portion was
halted prior to Maximum Tolerated Dose (MTD) determination.